of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (DART)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00925717
First received: June 19, 2009
Last updated: January 25, 2010
Last verified: January 2010
  Purpose

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.


Condition
Low Density Lipoprotein Cholesterol Goal Achievement

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Investigate LDL-C goal achievement rate according to ADA recommendation [ Time Frame: Within the last 6 months from the date of data entry. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Investigate reduction of 10-year risk for CHD by using UKPDS risk engine [ Time Frame: Within the last 6 months from the date of data entry. ] [ Designated as safety issue: No ]

Enrollment: 4045
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
2500 patients
Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.

Criteria

Inclusion Criteria:

  • Subjects who was diagnosed as diabetes
  • Subjects who was diagnosed as dyslipidaemia or takes lipid lowering medication
  • Clinic visit in the past 6 months more than once

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00925717

Locations
Korea, Republic of
Research Site
Cheonan-si, Chungchungnam-do, Korea, Republic of
Research Site
Ansan-si, Gyeonggi-do, Korea, Republic of
Research Site
Anyang-si, Gyeonggi-do, Korea, Republic of
Research Site
Bucheon-si, Gyeonggi-do, Korea, Republic of
Research Site
Goyang-si, Gyeonggi-do, Korea, Republic of
Research Site
Seongnam-si, Gyeonggi-do, Korea, Republic of
Research Site
Suwon-si, Gyeonggi-do, Korea, Republic of
Research Site
Uijeongbu-si, Gyeonggi-do, Korea, Republic of
Research Site
Gwangju-si, Jeollanam-do, Korea, Republic of
Research Site
Suncheon, Jeollanam-do, Korea, Republic of
Research Site
Jeonju-si, Jeonllabuk-do, Korea, Republic of
Research Site
Chuncheon, Kangwon-do, Korea, Republic of
Research Site
Chuncheon-si, Kangwon-do, Korea, Republic of
Research Site
Kang-Neung, Kangwon-do, Korea, Republic of
Research Site
Wonju-si, Kangwon-do, Korea, Republic of
Research Site
Busan-si, Korea, Republic of
Research Site
Cheonju-si, Korea, Republic of
Research Site
Daegu-si, Korea, Republic of
Research Site
Daejeon-si, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Incheon-si, Korea, Republic of
Research Site
Jeonju-si, Korea, Republic of
Research Site
Kwangju-si, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: MoonGyu Lee, Ph.D. Samsung Medical Center
  More Information

No publications provided

Responsible Party: Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00925717     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/1
Study First Received: June 19, 2009
Last Updated: January 25, 2010
Health Authority: Korea: N/A

Keywords provided by AstraZeneca:
ADA recommendation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on April 15, 2014